Crixivan indinavir HIV protease inhibitor: Marketed

Merck discontinued the evaluation of twice-daily dosing (1200 mg every 12 hours) of Crixivan in combination with reverse transcriptase inhibitors (Glaxo-Wellcome's AZT and BioChem Pharma's 3TC), and...